Pulchinenoside A (Anemoside A3)是一种来源于白头翁的天然三萜皂苷。Pulchinenoside A可通过增强海马突触可塑性和调节NMDA受体来改善认知功能。
Cas No.:129724-84-1
Sample solution is provided at 25 µL, 10mM.
Pulchinenoside A (Anemoside A3) is a natural triterpenoid saponin derived from Pulsatilla chinensis. Pulchinenoside A improves cognitive function by enhancing hippocampal synaptic plasticity and modulating NMDA receptors[1-2]. Pulchinenoside A is applicable for research related to neurodegenerative diseases, cerebral ischemia/stroke, and tumors[3-4].
In vitro, K562 cells were treated with Pulchinenoside A (0-300μM) for 48 hours. Pulchinenoside A significantly inhibited cell proliferation[5]. Mouse bone marrow-derived macrophages (BMDMs) were pretreated with Pulchinenoside A for 24 hours, followed by stimulation with IL-4 (20ng/mL) to induce M2 polarization. Pulchinenoside A significantly suppressed the expression of the M2 macrophage surface marker CD206 and downregulated the mRNA levels of M2 signature genes, including ARG-1, Fizz1, and Ym1[6].
In vivo, C57BL/6 mice were treated with Pulchinenoside A (100mg/kg; oral; daily) for 2 weeks. Pulchinenoside A significantly enhanced theta-burst stimulation-induced long-term potentiation in the hippocampal CA3-CA1 pathway and improved spatial reference memory formation in the Morris water maze test. In Sprague-Dawley rats subjected to middle cerebral artery occlusion, a single oral administration of Pulchinenoside A (100mg/kg) at 6 hours post-ischemia significantly reduced brain infarct volume and improved neurological deficit scores[7]. 10-week-old female C57BL/6 mice with experimental autoimmune encephalomyelitis (EAE) were treated daily with Pulchinenoside A (100mg/kg; oral) from day 2 post-induction until the end of the experiment (12 days). Pulchinenoside A significantly reduced the clinical disease score and decreased inflammatory infiltration and demyelination in the spinal cord[8].
References:
[1] Zhang DM, Lin SM, Lau CW, et al. Anemoside A3-induced relaxation in rat renal arteries: role of endothelium and Ca2+ channel inhibition. Planta Med. 2010 Nov;76(16):1814-9.
[2] Gao XD, Ye WC, Yu AC, et al. Pulsatilloside A and anemoside A3 protect PC12 cells from apoptosis induced by sodium cyanide and glucose deprivation. Planta Med. 2003 Feb;69(2):171-4.
[3] Yin L, Fan Z, Liu P, et al. Anemoside A3 activates TLR4-dependent M1-phenotype macrophage polarization to represses breast tumor growth and angiogenesis. Toxicol Appl Pharmacol. 2021 Dec 1;432:115755.
[4] Wang CM, Lin ZH, Lin ZQ, et al. Anemoside A3 rapidly reverses depression-like behaviors and weakening of excitatory synaptic transmission in mouse models of depression. J Psychopharmacol. 2019 Jan;33(1):37-50.
[5] Liu M, Zhao X, Xiao L, et al. Cytotoxicity of the compounds isolated from Pulsatilla chinensis saponins and apoptosis induced by 23-hydroxybetulinic acid. Pharm Biol. 2015 Jan;53(1):1-9.
[6] Liu P, Liu Y, Chen L, et al. Anemoside A3 Inhibits Macrophage M2-Like Polarization to Prevent Triple-Negative Breast Cancer Metastasis. Molecules. 2023 Feb 7;28(4):1611.
[7] Ip FC, Fu WY, Cheng EY, et al. Anemoside A3 Enhances Cognition through the Regulation of Synaptic Function and Neuroprotection. Neuropsychopharmacology. 2015 Jul;40(8):1877-87.
[8] Ip FCF, Ng YP, Or TCT, et al. Anemoside A3 ameliorates experimental autoimmune encephalomyelitis by modulating T helper 17 cell response. PLoS One. 2017 Jul 31;12(7):e0182069.
Pulchinenoside A (Anemoside A3)是一种来源于白头翁的天然三萜皂苷。Pulchinenoside A可通过增强海马突触可塑性和调节NMDA受体来改善认知功能[1-2]。Pulchinenoside A可用于神经退行性疾病、脑缺血/中风和肿瘤的相关研究[3-4]。
在体外,Pulchinenoside A(0-300μM)处理K562细胞48小时。Pulchinenoside A能显著抑制细胞增殖 [5]。Pulchinenoside A预处理小鼠骨髓来源巨噬细胞(BMDM)24小时,随后以IL-4(20ng/mL)刺激诱导M2型极化。Pulchinenoside A可显著抑制M2型巨噬细胞表面标志物CD206的表达,并下调M2型特征基因ARG-1、Fizz1和Ym1的mRNA水平[6]。
在体内,Pulchinenoside A(100mg/kg;每日口服)处理C57BL/6小鼠2周。Pulchinenoside A显著增强了海马CA3-CA1通路的θ波爆发刺激诱导的长时程增强,并改善了其在莫里斯水迷宫测试中的空间参考记忆形成;Pulchinenoside A(100mg/kg;单次口服)在缺血后6小时给予Sprague-Dawley大鼠,显著减小了脑梗死体积并改善了神经功能缺损评分[7]。Pulchinenoside A(100mg/kg;每日口服)处理10周龄雌性C57BL/6小鼠,从实验性自身免疫性脑脊髓炎(EAE)诱导后第二天开始直至实验结束(12天)。Pulchinenoside A能显著降低疾病的临床评分,并减少脊髓中的炎症浸润和脱髓鞘病变[8]。
| Cell experiment [1]: | |
Cell lines | K562 cells (human chronic myelogenous leukemia cell line) |
Preparation Method | K562 cells were treated with Pulchinenoside A (0-300μM) for 48 hours, and cell viability was assessed by the MTT assay. |
Reaction Conditions | 0-300μM; 48h. |
Applications | Pulchinenoside A significantly inhibited the proliferation of K562 cells. |
| Animal experiment [2]: | |
Animal models | 10-week-old female C57BL/6 mice |
Preparation Method | Mice were immunized with MOG35-55peptide to induce experimental autoimmune encephalomyelitis (EAE). Starting from the day after immunization (day 0), mice were treated daily with Pulchinenoside A via oral gavage until the end of the experiment. |
Dosage form | 100mg/kg; oral gavage; daily administration for 12 days. |
Applications | Pulchinenoside A treatment significantly reduced the clinical severity of EAE and decreased inflammatory infiltrates and demyelination in the spinal cord. |
References: | |
| Cas No. | 129724-84-1 | SDF | |
| 别名 | 白头翁皂苷A3,Anemoside A3 | ||
| 化学名 | (3beta,4alpha)-3-[[2-O-(6-Deoxy-alpha-L-mannopyranosyl)-alpha-L-arabinopyranosyl]oxy]-23-hydroxylup-20(29)-en-28-oic acid;Pulchinenoside A | ||
| Canonical SMILES | CC1C(C(C(C(O1)OC2C(C(COC2OC3CCC4(C5CCC6C7C(CCC7(CCC6(C5(CCC4C3(C)CO)C)C)C(=O)O)C(=C)C)C)O)O)O)O)O | ||
| 分子式 | C41H66O12 | 分子量 | 750 |
| 溶解度 | ≥ 3.75mg/mL in EtOH with ultrasonic and warming | 储存条件 | Store at 2-8°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3333 mL | 6.6667 mL | 13.3333 mL |
| 5 mM | 266.7 μL | 1.3333 mL | 2.6667 mL |
| 10 mM | 133.3 μL | 666.7 μL | 1.3333 mL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















